Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy

Inclusion Criteria

• •History of biopsy documented prostate cancer (any Gleason score)
• •Past treatment with prostatectomy with or without salvage prostate/pelvic radiation or primary radiation (external beam or brachytherapy)
• •If past prostatectomy, pathologic stage no greater than T1-3, N1, M0
• •PSA recurrence with PSAdt \< 18 months. There is no minimum PSA for prostatectomy patients. For patients treated with primary radiation therapy PSA should be greater than 2.0 ng/ml
• •No evidence of recurrent disease on exam, bone scan, CT/MRI abdomen/pelvis or CXR
• •Prior ADT allowed if \< 6 months and testosterone recovered to within 50 units (ng/dl) of normal range
• •ECOG Performance status of 0-1
• •Absolute neutrophil count of \>1,500
• •Platelet count \> 100,000
• •Hg \> 8g/dl
• •No history of bleeding or thromboses within the last 12 months that required medical intervention